Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nurix Therapeutics Inc (NQ: NRIX )

8.590 +0.110 (+1.30%)
Streaming Delayed Price Updated: 2:10 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,135
Open 8.500
Bid (Size) 8.580 (4)
Ask (Size) 8.610 (2)
Prev. Close 8.480
Today's Range 8.500 - 8.880
52wk Range 8.120 - 15.09
Shares Outstanding 47,147,781
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Cancer Focused Nurix Therapeutics Stock Trading Higher Today?
Nurix Therapeutics Inc (NASDAQ: NRIX) has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc (NASDAQ: SGEN) to advance a new class of medicines called... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Nurix Therapeutics
Via Benzinga

Performance

YTD
-20.83%
-20.83%
1 Month
-0.35%
-0.35%
3 Month
-10.71%
-10.71%
6 Month
-5.19%
-5.19%
1 Year
-30.33%
-30.33%

More News

Read More
Designer Brands, Calavo Growers, Couchbase And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Analyst Cuts Nurix Therapeutics Price Target By 38%, Cites Lymphoma Data
Via Benzinga
Analyst Ratings for Nurix Therapeutics
Via Benzinga
Nurix Therapeutics's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for Nurix Therapeutics
Via Benzinga
Nurix Therapeutics Inc. (NASDAQ: NRIX) Highlighted for Surprising Price Action
Via Investor Brand Network
Expert Ratings for Nurix Therapeutics
Via Benzinga
Gilead Exercises First License Option Under Agreement With Nurix Therapeutics
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
JPMorgan, Citigroup, QuidelOrtho And Other Big Stocks Moving Higher On Friday
Via Benzinga
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
From Gilead Sciences, Inc.
Via Business Wire
Analyst Ratings for Nurix Therapeutics
Via Benzinga
Nurix Therapeutics's Return On Capital Employed Overview
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Via Benzinga
The Top 5 Stocks Cathie Wood Bought and Sold This Week
Via InvestorPlace
CSX, Veris Residential And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Via Benzinga
Cathie Wood Loads Up Over $6.7M In Adobe Stock As It Tumbles 27% In A Month — Also Adds Stake In This Biopharma Company
Via Benzinga
Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday
Via Benzinga
Top Russell 2000 Stocks: Trading Opportunities For Next Week - Sunday, Sept. 11
Via Talk Markets
Tesla, Twitter And 76 Biggest Movers From Friday
Via Benzinga
Why Nurix Therapeutics Shares Are Rising Today
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.